{
  "id": 14343483,
  "title": "Earnings call transcript: PharmX posts 9% revenue growth in Q1 2026 as stock slips",
  "url": "https://urgent.news/2026/10/14/earnings-call-transcript-pharmx-posts-9-revenue-growth-in-q1-2026-as",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T01:38:29.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-pharmx-posts-9-revenue-growth-in-q1-2026-as-stock-slips-93CH-4947852"
  },
  "original_language": "en",
  "account": "PharmX Technologies reported a 9% increase in revenue for the first quarter of 2026, driven by a shift towards volume-based fees, expansion of its marketplace platform and maintaining a strong balance sheet. The company's shares remained flat or slightly declined, closing at $0.083 after trading as low as $0.084 during the session. Despite this modest price movement, PharmX's market capitalization remains near its low point of $0.08 per share, signaling investor caution despite the company's operational improvements.\n\nThe Q1 2026 results show that PharmX's recurring revenue has shifted to a more stable volume-based structure, now accounting for 24% of total recurring revenue, up from 20% in the prior year. Over 88% of FY2017 revenue is now recurring or contracted, providing the business with a more predictable foundation. The company's marketplace activity has also accelerated, with September gross transaction value (GTV) reaching AUD 6.9 million, a 150% increase from the previous quarter and 45% rise from the prior month. Orders on the Gateway EDI network increased by 12% year over year, with gross transaction value rising by 15%.\n\nManagement expressed ambition for FY2017, targeting double-digit revenue growth and cash flow breakeven, with a plan to achieve margin expansion in FY2018 and beyond. The company highlighted its central role in the pharmacy supply chain in Australia and New Zealand, boasting connectivity to 99% of pharmacies and all major suppliers, technology vendors and government agencies. PharmX's CEO, Tom Culver, described the business as \"critical infrastructure\" for the industry, noting about AUD 26 billion in annual platform volumes.\n\nDespite the positive revenue growth, PharmX continues to operate at a loss, with an EBITDA of negative $1.21 million over the last twelve months. The company's balance sheet remains relatively small, with AUD 2.6 million in cash as of June 30, 2016, and a current ratio of 2.33, indicating sufficient liquidity to cover short-term obligations. Investors should monitor PharmX closely as the company adopts its new revenue model and pursues growth targets.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Earnings call transcript: Core Lithium Q1 2026 shares fall as restart advances",
        "url": "https://urgent.news/2026/10/14/earnings-call-transcript-core-lithium-q1-2026-shares-fall-as-restart",
        "published": "2026-10-14T01:28:45.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}